# Octreotide LAR in the Induction of Immunologic Response in NENs Patients

> **NCT04129255** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute, Naples** · enrollment: 34 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Octreotide Acetate

## Key facts

- **NCT ID:** NCT04129255
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-28
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129255, "Octreotide LAR in the Induction of Immunologic Response in NENs Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04129255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*